1
|
Todorova T, Boyadzhiev K, Dimitrov M, Parvanova P. Bee venom genotoxicity on Saccharomyces cerevisiae cells - The role of mitochondria and YAP1 transcription factor. Toxicology 2024; 503:153768. [PMID: 38442839 DOI: 10.1016/j.tox.2024.153768] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/04/2024] [Revised: 02/22/2024] [Accepted: 03/01/2024] [Indexed: 03/07/2024]
Abstract
The present work aims to clarify the genotype differences of a model organism Saccharomyces cerevisiae in response to bee venom. The study evaluated various endpoints including cell survival, induction of physiologically active superoxide anions, mitotic gene conversion, mitotic crossing-over, reverse mutations, DNA double-strand breaks, and Ty1 retrotransposition. The role of the intact mitochondria and the YAP1 transcription factor was also evaluated. Our results indicate a genotype-specific response. The first experimental evidence has been provided that bee venom induces physiologically active superoxide anions and DNA double-strand breaks in S. cerevisiae. The lack of oxidative phosphorylation due to disrupted or missing mitochondrial DNA reduces but not diminishes the cytotoxicity of bee venom. The possible modes of action could be considered direct damage to membranes (cytotoxic effect) and indirect damage to DNA through oxidative stress (genotoxic effect). YAP1 transcription factor was not found to be directly involved in cell defense against bee venom treatment.
Collapse
Affiliation(s)
- Teodora Todorova
- Institute of Biodiversity and Ecosystem Research, Bulgarian Academy of Sciences, 2 Gagarin str., Sofia 1113, Bulgaria.
| | - Krassimir Boyadzhiev
- Institute of Biodiversity and Ecosystem Research, Bulgarian Academy of Sciences, 2 Gagarin str., Sofia 1113, Bulgaria
| | - Martin Dimitrov
- Institute of Biodiversity and Ecosystem Research, Bulgarian Academy of Sciences, 2 Gagarin str., Sofia 1113, Bulgaria
| | - Petya Parvanova
- Institute of Biodiversity and Ecosystem Research, Bulgarian Academy of Sciences, 2 Gagarin str., Sofia 1113, Bulgaria
| |
Collapse
|
2
|
Sinha B, Choudhury Y. Revisiting edible insects as sources of therapeutics and drug delivery systems for cancer therapy. Front Pharmacol 2024; 15:1345281. [PMID: 38370484 PMCID: PMC10869617 DOI: 10.3389/fphar.2024.1345281] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/27/2023] [Accepted: 01/22/2024] [Indexed: 02/20/2024] Open
Abstract
Cancer has been medicine's most formidable foe for long, and the rising incidence of the disease globally has made effective cancer therapy a significant challenge. Drug discovery is targeted at identifying efficacious compounds with minimal side effects and developments in nanotechnology and immunotherapy have shown promise in the fight against this complicated illness. Since ancient times, insects and insect-derived products have played a significant role in traditional medicine across several communities worldwide. The aim of this study was to inspect the traditional use of edible insects in various cultures and to explore their modern use in cancer therapy. Edible insects are sources of nutrients and a variety of beneficial substances with anticancer and immunomodulatory potential. Recently, insect derived bioactive-components have also been used as nanoparticles either in combination with chemotherapeutics or as a nano-cargo for the enhanced delivery of chemotherapeutic drugs due to their high biocompatibility, low bio-toxicity, and their antioxidant and anticancer effects. The crude extracts of different edible insects and their active components such as sericin, cecropin, solenopsin, melittin, antimicrobial peptides and fibroin produce anti-cancer and immunomodulatory effects by various mechanisms which have been discussed in this review.
Collapse
|
3
|
Dashevsky D, Baumann K, Undheim EAB, Nouwens A, Ikonomopoulou MP, Schmidt JO, Ge L, Kwok HF, Rodriguez J, Fry BG. Functional and Proteomic Insights into Aculeata Venoms. Toxins (Basel) 2023; 15:toxins15030224. [PMID: 36977115 PMCID: PMC10053895 DOI: 10.3390/toxins15030224] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/09/2022] [Revised: 03/07/2023] [Accepted: 03/12/2023] [Indexed: 03/19/2023] Open
Abstract
Aculeate hymenopterans use their venom for a variety of different purposes. The venom of solitary aculeates paralyze and preserve prey without killing it, whereas social aculeates utilize their venom in defence of their colony. These distinct applications of venom suggest that its components and their functions are also likely to differ. This study investigates a range of solitary and social species across Aculeata. We combined electrophoretic, mass spectrometric, and transcriptomic techniques to characterize the compositions of venoms from an incredibly diverse taxon. In addition, in vitro assays shed light on their biological activities. Although there were many common components identified in the venoms of species with different social behavior, there were also significant variations in the presence and activity of enzymes such as phospholipase A2s and serine proteases and the cytotoxicity of the venoms. Social aculeate venom showed higher presence of peptides that cause damage and pain in victims. The venom-gland transcriptome from the European honeybee (Apis mellifera) contained highly conserved toxins which match those identified by previous investigations. In contrast, venoms from less-studied taxa returned limited results from our proteomic databases, suggesting that they contain unique toxins.
Collapse
Affiliation(s)
- Daniel Dashevsky
- Australian National Insect Collection, Commonwealth Scientific & Industrial Research Organisation, Canberra, ACT 2601, Australia
- Correspondence: (D.D.); (B.G.F.)
| | - Kate Baumann
- Venom Evolution Lab, School of Biological Sciences, The University of Queensland, St. Lucia, QLD 4072, Australia
| | - Eivind A. B. Undheim
- Centre for Ecological and Evolutionary Synthesis, Department of Bioscience, University of Oslo, N-0316 Oslo, Norway
| | - Amanda Nouwens
- School of Chemistry and Molecular Biosciences, University of Queensland, St. Lucia, QLD 4072, Australia
| | - Maria P. Ikonomopoulou
- Translational Venomics Group, Madrid Institute for Advanced Studies in Food, 4075 Madrid, Spain
| | - Justin O. Schmidt
- Southwestern Biological Institute, 1961 W. Brichta Dr., Tucson, AZ 85745, USA
| | - Lilin Ge
- State Key Laboratory Cultivation Base for TCM Quality and Efficacy, School of Pharmacy, Nanjing University of Chinese Medicine, 138 Xianlin Avenue, Qixia District, Nanjing 210046, China
- Institute of Translational Medicine, Department of Biomedical Sciences, Faculty of Health Sciences, University of Macau, Avenida da Universidade, Taipa, Macau
| | - Hang Fai Kwok
- Institute of Translational Medicine, Department of Biomedical Sciences, Faculty of Health Sciences, University of Macau, Avenida da Universidade, Taipa, Macau
| | - Juanita Rodriguez
- Australian National Insect Collection, Commonwealth Scientific & Industrial Research Organisation, Canberra, ACT 2601, Australia
| | - Bryan G. Fry
- Venom Evolution Lab, School of Biological Sciences, The University of Queensland, St. Lucia, QLD 4072, Australia
- Correspondence: (D.D.); (B.G.F.)
| |
Collapse
|
4
|
Sjakste N, Gajski G. A Review on Genotoxic and Genoprotective Effects of Biologically Active Compounds of Animal Origin. Toxins (Basel) 2023; 15:165. [PMID: 36828477 PMCID: PMC9961038 DOI: 10.3390/toxins15020165] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/02/2023] [Revised: 02/15/2023] [Accepted: 02/15/2023] [Indexed: 02/22/2023] Open
Abstract
Envenomation by animal venoms remains a serious medical and social problem, especially in tropical countries. On the other hand, animal venoms are widely used as a source of biologically active compounds for the development of novel drugs. Numerous derivatives of animal venoms are already used in clinical practice. When analysing the mechanisms of action of animal venoms, attention is usually focused on the main target of the venom's enzymes and peptides such as neurotoxic, cytotoxic or haemorrhagic effects. In the present review, we would like to draw attention to the "hidden" effects of animal venoms and their derivatives in regard to DNA damage and/or protection against DNA damage. Alkaloids and terpenoids isolated from sponges such as avarol, ingenamine G or variolin B manifest the capability to bind DNA in vitro and produce DNA breaks. Trabectidin, isolated from a sea squirt, also binds and damages DNA. A similar action is possible for peptides isolated from bee and wasp venoms such as mastoparan, melectin and melittin. However, DNA lesions produced by the crude venoms of jellyfish, scorpions, spiders and snakes arise as a consequence of cell membrane damage and the subsequent oxidative stress, whereas certain animal venoms or their components produce a genoprotective effect. Current research data point to the possibility of using animal venoms and their components in the development of various potential therapeutic agents; however, before their possible clinical use the route of injection, molecular target, mechanism of action, exact dosage, possible side effects and other fundamental parameters should be further investigated.
Collapse
Affiliation(s)
- Nikolajs Sjakste
- Department of Medical Biochemistry, Faculty of Medicine, University of Latvia, 1004 Riga, Latvia
- Genetics and Bioinformatics, Institute of Biology, University of Latvia, 1004 Riga, Latvia
| | - Goran Gajski
- Mutagenesis Unit, Institute for Medical Research and Occupational Health, 10000 Zagreb, Croatia
| |
Collapse
|
5
|
Ullah A, Aldakheel FM, Anjum SI, Raza G, Khan SA, Tlak Gajger I. Pharmacological properties and therapeutic potential of honey bee venom. Saudi Pharm J 2023; 31:96-109. [PMID: 36685303 PMCID: PMC9845117 DOI: 10.1016/j.jsps.2022.11.008] [Citation(s) in RCA: 6] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/10/2022] [Accepted: 11/09/2022] [Indexed: 11/17/2022] Open
Abstract
Honey bee venom (BV) is a valuable product, and has a wide range of biological effects, and its use is rapidly increasing in apitherapy. Therefore, the current study, we reviewed the existing knowledge about BV composition and its numerous pharmacological properties for future research and use. Honey bee venom or apitoxin is produced in the venom gland in the honey bee abdomen. Adult bees use it as a primary colony defense mechanism. It is composed of many biologically active substances including peptides, enzymes, amines, amino acids, phospholipids, minerals, carbohydrates as well as some volatile components. Melittin and phospholipase A2 are the most important components of BV, having anti-cancer, antimicrobial, anti-inflammatory, anti-arthritis, anti-nociceptive and other curative potentials. Therefore, in medicine, BV has been used for centuries against different diseases like arthritis, rheumatism, back pain, and various inflammatory infections. Nowadays, BV or its components separately, are used for the treatment of various diseases in different countries as a natural medicine with limited side effects. Consequently, scientists as well as several pharmaceutical companies are trying to get a new understanding about BV, its substances and its activity for more effective use of this natural remedy in modern medicine.
Collapse
Affiliation(s)
- Amjad Ullah
- Department of Zoology, Kohat University of Science and Technology, Kohat 26000, Khyber Pakhtunkhwa, Pakistan
| | - Fahad Mohammed Aldakheel
- Department of Clinical Laboratory Sciences, College of Applied Medical Sciences, King Saud University, Riyadh 11433, Saudi Arabia,Prince Sattam bin Abdulaziz Research Chair for Epidemiology and Public Health, College of Medicine, King Saud University, Riyadh 11461, Saudi Arabia
| | - Syed Ishtiaq Anjum
- Department of Zoology, Kohat University of Science and Technology, Kohat 26000, Khyber Pakhtunkhwa, Pakistan,Corresponding author.
| | - Ghulam Raza
- Department of Biological Sciences, University of Baltistan, Skardu, Pakistan
| | - Saeed Ahmad Khan
- Department of Pharmacy, Institute of Chemical and Pharmaceutical Sciences, Kohat University of Science and Technology, Kohat, Khyber Pakhtunkhwa, Pakistan
| | - Ivana Tlak Gajger
- Department for Biology and Pathology of Fish and Bees, Faculty of Veterinary Medicine University of Zagreb, Zagreb, Croatia
| |
Collapse
|
6
|
Domingo IK, Latif A, Bhavsar AP. Pro-Inflammatory Signalling PRRopels Cisplatin-Induced Toxicity. Int J Mol Sci 2022; 23:7227. [PMID: 35806229 PMCID: PMC9266867 DOI: 10.3390/ijms23137227] [Citation(s) in RCA: 28] [Impact Index Per Article: 14.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/31/2022] [Revised: 06/26/2022] [Accepted: 06/27/2022] [Indexed: 02/04/2023] Open
Abstract
Cisplatin is a platinum-based chemotherapeutic that has long since been effective against a variety of solid-cancers, substantially improving the five-year survival rates for cancer patients. Its use has also historically been limited by its adverse drug reactions, or cisplatin-induced toxicities (CITs). Of these reactions, cisplatin-induced nephrotoxicity (CIN), cisplatin-induced peripheral neuropathy (CIPN), and cisplatin-induced ototoxicity (CIO) are the three most common of several CITs recognised thus far. While the anti-cancer activity of cisplatin is well understood, the mechanisms driving its toxicities have only begun to be defined. Most of the literature pertains to damage caused by oxidative stress that occurs downstream of cisplatin treatment, but recent evidence suggests that the instigator of CIT development is inflammation. Cisplatin has been shown to induce pro-inflammatory signalling in CIN, CIPN, and CIO, all of which are associated with persisting markers of inflammation, particularly from the innate immune system. This review covered the hallmarks of inflammation common and distinct between different CITs, the role of innate immune components in development of CITs, as well as current treatments targeting pro-inflammatory signalling pathways to conserve the use of cisplatin in chemotherapy and improve long-term health outcomes of cancer patients.
Collapse
Affiliation(s)
| | | | - Amit P. Bhavsar
- Department of Medical Microbiology and Immunology, University of Alberta, Edmonton, AB T6G 2E1, Canada; (I.K.D.); (A.L.)
| |
Collapse
|
7
|
Klupczynska A, Plewa S, Dereziński P, Garrett TJ, Rubio VY, Kokot ZJ, Matysiak J. Identification and quantification of honeybee venom constituents by multiplatform metabolomics. Sci Rep 2020; 10:21645. [PMID: 33303913 PMCID: PMC7729905 DOI: 10.1038/s41598-020-78740-1] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/24/2020] [Accepted: 11/27/2020] [Indexed: 02/06/2023] Open
Abstract
Honeybee (Apis mellifera) venom (HBV) has been a subject of extensive proteomics research; however, scarce information on its metabolite composition can be found in the literature. The aim of the study was to identify and quantify the metabolites present in HBV. To gain the highest metabolite coverage, three different mass spectrometry (MS)-based methodologies were applied. In the first step, untargeted metabolomics was used, which employed high-resolution, accurate-mass Orbitrap MS. It allowed obtaining a broad overview of HBV metabolic components. Then, two targeted metabolomics approaches, which employed triple quadrupole MS, were applied to quantify metabolites in HBV samples. The untargeted metabolomics not only confirmed the presence of amines, amino acids, carbohydrates, and organic acids in HBV, but also provided information on venom components from other metabolite classes (e.g., nucleosides, alcohols, purine and pyrimidine derivatives). The combination of three MS-based metabolomics platforms facilitated the identification of 214 metabolites in HBV samples, among which 138 were quantified. The obtaining of the wide free amino acid profiles of HBV is one of the project’s achievements. Our study contributed significantly to broadening the knowledge about HBV composition and should be continued to obtain the most comprehensive metabolite profile of HBV.
Collapse
Affiliation(s)
- Agnieszka Klupczynska
- Department of Inorganic and Analytical Chemistry, Poznan University of Medical Sciences, 60-780, Poznan, Poland.
| | - Szymon Plewa
- Department of Inorganic and Analytical Chemistry, Poznan University of Medical Sciences, 60-780, Poznan, Poland
| | - Paweł Dereziński
- Department of Inorganic and Analytical Chemistry, Poznan University of Medical Sciences, 60-780, Poznan, Poland
| | - Timothy J Garrett
- Department of Pathology, Immunology and Laboratory Medicine, College of Medicine, University of Florida, Gainesville, FL, 32610, USA
| | - Vanessa Y Rubio
- Department of Pathology, Immunology and Laboratory Medicine, College of Medicine, University of Florida, Gainesville, FL, 32610, USA
| | - Zenon J Kokot
- Faculty of Health Sciences, Calisia University - Kalisz, Poland, 62-800, Kalisz, Poland
| | - Jan Matysiak
- Department of Inorganic and Analytical Chemistry, Poznan University of Medical Sciences, 60-780, Poznan, Poland
| |
Collapse
|
8
|
Duffy C, Sorolla A, Wang E, Golden E, Woodward E, Davern K, Ho D, Johnstone E, Pfleger K, Redfern A, Iyer KS, Baer B, Blancafort P. Honeybee venom and melittin suppress growth factor receptor activation in HER2-enriched and triple-negative breast cancer. NPJ Precis Oncol 2020; 4:24. [PMID: 32923684 PMCID: PMC7463160 DOI: 10.1038/s41698-020-00129-0] [Citation(s) in RCA: 78] [Impact Index Per Article: 19.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/09/2019] [Accepted: 07/28/2020] [Indexed: 12/13/2022] Open
Abstract
Despite decades of study, the molecular mechanisms and selectivity of the biomolecular components of honeybee (Apis mellifera) venom as anticancer agents remain largely unknown. Here, we demonstrate that honeybee venom and its major component melittin potently induce cell death, particularly in the aggressive triple-negative and HER2-enriched breast cancer subtypes. Honeybee venom and melittin suppress the activation of EGFR and HER2 by interfering with the phosphorylation of these receptors in the plasma membrane of breast carcinoma cells. Mutational studies reveal that a positively charged C-terminal melittin sequence mediates plasma membrane interaction and anticancer activity. Engineering of an RGD motif further enhances targeting of melittin to malignant cells with minimal toxicity to normal cells. Lastly, administration of melittin enhances the effect of docetaxel in suppressing breast tumor growth in an allograft model. Our work unveils a molecular mechanism underpinning the anticancer selectivity of melittin, and outlines treatment strategies to target aggressive breast cancers.
Collapse
Affiliation(s)
- Ciara Duffy
- School of Human Sciences, The University of Western Australia, Perth, WA 6009 Australia.,Cancer Epigenetics Group, Harry Perkins Institute of Medical Research, Perth, WA 6009 Australia.,Plant Energy Biology, The University of Western Australia, Perth, WA 6009 Australia.,Centre for Medical Research, The University of Western Australia, Perth, WA 6009 Australia
| | - Anabel Sorolla
- Cancer Epigenetics Group, Harry Perkins Institute of Medical Research, Perth, WA 6009 Australia.,Centre for Medical Research, The University of Western Australia, Perth, WA 6009 Australia
| | - Edina Wang
- Cancer Epigenetics Group, Harry Perkins Institute of Medical Research, Perth, WA 6009 Australia.,Centre for Medical Research, The University of Western Australia, Perth, WA 6009 Australia
| | - Emily Golden
- Cancer Epigenetics Group, Harry Perkins Institute of Medical Research, Perth, WA 6009 Australia.,Centre for Medical Research, The University of Western Australia, Perth, WA 6009 Australia
| | - Eleanor Woodward
- Cancer Epigenetics Group, Harry Perkins Institute of Medical Research, Perth, WA 6009 Australia.,Centre for Medical Research, The University of Western Australia, Perth, WA 6009 Australia
| | - Kathleen Davern
- Centre for Medical Research, The University of Western Australia, Perth, WA 6009 Australia.,Monoclonal Antibody (MAb) Facility, Harry Perkins Institute of Medical Research, Perth, WA 6009 Australia
| | - Diwei Ho
- School of Molecular Sciences, The University of Western Australia, Perth, WA 6009 Australia
| | - Elizabeth Johnstone
- Centre for Medical Research, The University of Western Australia, Perth, WA 6009 Australia.,Molecular Endocrinology and Pharmacology, Harry Perkins Institute of Medical Research, Perth, WA 6009 Australia.,Australian Research Council Centre for Personalised Therapeutics Technologies, Perth, Australia
| | - Kevin Pfleger
- Centre for Medical Research, The University of Western Australia, Perth, WA 6009 Australia.,Molecular Endocrinology and Pharmacology, Harry Perkins Institute of Medical Research, Perth, WA 6009 Australia.,Australian Research Council Centre for Personalised Therapeutics Technologies, Perth, Australia.,Dimerix Limited; Nedlands, Perth, WA 6009 Australia
| | - Andrew Redfern
- School of Medicine, The University of Western Australia, Perth, WA 6009 Australia
| | - K Swaminathan Iyer
- Monoclonal Antibody (MAb) Facility, Harry Perkins Institute of Medical Research, Perth, WA 6009 Australia
| | - Boris Baer
- Centre for Integrative Bee Research (CIBER), Department of Entomology; University of California Riverside, Riverside, CA 92521 USA
| | - Pilar Blancafort
- School of Human Sciences, The University of Western Australia, Perth, WA 6009 Australia.,Cancer Epigenetics Group, Harry Perkins Institute of Medical Research, Perth, WA 6009 Australia.,Centre for Medical Research, The University of Western Australia, Perth, WA 6009 Australia.,The Greehey Children's Cancer Research Institute, The University of Texas Health Science Center at San Antonio, San Antonio, TX 78229 USA
| |
Collapse
|
9
|
Huerta-Rey M, Anselme C, Cherqui A, Decocq G. Exploration Through the Venoms from Hymenoptera as Potential Therapeutic Agents in Cancer Therapy. INT J PHARMACOL 2017. [DOI: 10.3923/ijp.2017.507.515] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
10
|
Alonezi S, Tusiimire J, Wallace J, Dufton MJ, Parkinson JA, Young LC, Clements CJ, Park JK, Jeon JW, Ferro VA, Watson DG. Metabolomic Profiling of the Synergistic Effects of Melittin in Combination with Cisplatin on Ovarian Cancer Cells. Metabolites 2017; 7:metabo7020014. [PMID: 28420117 PMCID: PMC5487985 DOI: 10.3390/metabo7020014] [Citation(s) in RCA: 27] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/17/2017] [Revised: 04/10/2017] [Accepted: 04/12/2017] [Indexed: 12/13/2022] Open
Abstract
Melittin, the main peptide present in bee venom, has been proposed as having potential for anticancer therapy; the addition of melittin to cisplatin, a first line treatment for ovarian cancer, may increase the therapeutic response in cancer treatment via synergy, resulting in improved tolerability, reduced relapse, and decreased drug resistance. Thus, this study was designed to compare the metabolomic effects of melittin in combination with cisplatin in cisplatin-sensitive (A2780) and resistant (A2780CR) ovarian cancer cells. Liquid chromatography (LC) coupled with mass spectrometry (MS) was applied to identify metabolic changes in A2780 (combination treatment 5 μg/mL melittin + 2 μg/mL cisplatin) and A2780CR (combination treatment 2 μg/mL melittin + 10 μg/mL cisplatin) cells. Principal components analysis (PCA) and orthogonal partial least squares discriminant analysis (OPLS-DA) multivariate data analysis models were produced using SIMCA-P software. All models displayed good separation between experimental groups and high-quality goodness of fit (R2) and goodness of prediction (Q2), respectively. The combination treatment induced significant changes in both cell lines involving reduction in the levels of metabolites in the tricarboxylic acid (TCA) cycle, oxidative phosphorylation, purine and pyrimidine metabolism, and the arginine/proline pathway. The combination of melittin with cisplatin that targets these pathways had a synergistic effect. The melittin-cisplatin combination had a stronger effect on the A2780 cell line in comparison with the A2780CR cell line. The metabolic effects of melittin and cisplatin in combination were very different from those of each agent alone.
Collapse
Affiliation(s)
- Sanad Alonezi
- Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, Glasgow G4 0RE, UK.
| | - Jonans Tusiimire
- Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, Glasgow G4 0RE, UK.
- Department of Pharmacy, Faculty of Medicine, Mbarara University of Science and Technology, P.O. Box 1410 Mbarara, Uganda.
| | - Jennifer Wallace
- WestCHEM Department of Pure and Applied Chemistry, University of Strathclyde, Glasgow G1 1XL, UK.
| | - Mark J Dufton
- WestCHEM Department of Pure and Applied Chemistry, University of Strathclyde, Glasgow G1 1XL, UK.
| | - John A Parkinson
- WestCHEM Department of Pure and Applied Chemistry, University of Strathclyde, Glasgow G1 1XL, UK.
| | - Louise C Young
- Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, Glasgow G4 0RE, UK.
| | - Carol J Clements
- Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, Glasgow G4 0RE, UK.
| | - Jin-Kyu Park
- #204, Beesen Co. Ltd., Bio Venture Town, Yuseong Daero 1662, Dae Jeon 34054, Korea.
| | - Jong-Woon Jeon
- #204, Beesen Co. Ltd., Bio Venture Town, Yuseong Daero 1662, Dae Jeon 34054, Korea.
| | - Valerie A Ferro
- Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, Glasgow G4 0RE, UK.
| | - David G Watson
- Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, Glasgow G4 0RE, UK.
| |
Collapse
|
11
|
Rožman M, Petrović M. Bquant - Novel script for batch quantification of LCMS data. MethodsX 2016; 3:520-524. [PMID: 27709068 PMCID: PMC5040634 DOI: 10.1016/j.mex.2016.09.001] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/30/2016] [Accepted: 09/12/2016] [Indexed: 11/04/2022] Open
Abstract
Quantitative target analysis by liquid chromatography coupled to mass spectrometry (LCMS) is ubiquitous in environmental, metabolomic and toxicological studies. Targeted LCMS methods are capable of the simultaneous determination of literally hundreds of analytes. Although acquiring of instrumental data is very fast, data post-processing i.e. quantification can be time consuming step (and)or dependent to various commercial software packages. In attempt to facilitate this drawback Wolfram Mathematica script for batch quantification of LCMS data was created. Script works with direct outputs of integration algorithms created by different instrument control software’s or custom created outputs. Key benefits of Bquant script are: simple and automated routine for batch mode quantification vast improvement in processing time (especially compared to manual interpretation) data can be quickly re-analysed using different inputs
Script was validated on various datasets and some of these were provided as working examples.
Collapse
Affiliation(s)
- Marko Rožman
- Ruđer Bošković Institute, Bijenička cesta 54, 10000 Zagreb, Croatia
| | - Mira Petrović
- Catalan Institute for Water Research (ICRA), Carrer Emili Grahit 101, 17003 Girona, Spain
| |
Collapse
|
12
|
Gajski G, Čimbora-Zovko T, Rak S, Osmak M, Garaj-Vrhovac V. Antitumour action on human glioblastoma A1235 cells through cooperation of bee venom and cisplatin. Cytotechnology 2016; 68:1197-205. [PMID: 25916941 PMCID: PMC4960167 DOI: 10.1007/s10616-015-9879-4] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/24/2014] [Accepted: 04/15/2015] [Indexed: 01/06/2023] Open
Abstract
Cisplatin (cDDP) is one of the most widely used anticancer-drugs in both therapy and research. However, cDDP-resistance is the greatest obstacle for the successful treatment of cancer patients. In the present study, the possible joint anticancer effect of bee venom (BV), as a natural toxin, and cDDP towards human glioblastoma A1235 cells was evaluated. Treatment with BV alone in concentrations of 2.5-30 μg/ml displayed dose-dependent cytotoxicity towards A1235 cells, as evaluated with different cytotoxicity assays (MTT, Cristal violet and Trypan blue exclusion assay), with an IC50 value of 22.57 μg/ml based on the MTT results. Furthermore, BV treatment induced necrosis, which was confirmed by typical morphological features and fast staining with ethidium-bromide dye. Pre-treatment with BV induced cell sensitization to cDDP, indicating that BV could improve the killing effect of selected cells when combined with cDDP. The isobologram method used to determine the extent of synergism in combining two agents to examine their possible therapeutic effect showed that combined treatment induced an additive and/or synergistic effect towards selected cells depending on the concentration of both. Hence, a greater anticancer effect could be triggered if BV was used in the course of chemotherapy. The obtained results indicate that joint treatment with BV could be useful from the point of minimizing the cDDP concentration during chemotherapy, thus reducing and/or postponing the development of drug resistance. Our data, in accordance with previously reported results, suggests that BV could be used in the development of a new strategy for cancer treatment.
Collapse
Affiliation(s)
- Goran Gajski
- Mutagenesis Unit, Institute for Medical Research and Occupational Health, Ksaverska cesta 2, 10000, Zagreb, Croatia
| | - Tamara Čimbora-Zovko
- Laboratory for Genotoxic Agents, Division of Molecular Biology, Ruđer Bošković Institute, Bijenička cesta 54, 10000, Zagreb, Croatia
| | - Sanjica Rak
- Laboratory for Genotoxic Agents, Division of Molecular Biology, Ruđer Bošković Institute, Bijenička cesta 54, 10000, Zagreb, Croatia
| | - Maja Osmak
- Laboratory for Genotoxic Agents, Division of Molecular Biology, Ruđer Bošković Institute, Bijenička cesta 54, 10000, Zagreb, Croatia
| | - Vera Garaj-Vrhovac
- Mutagenesis Unit, Institute for Medical Research and Occupational Health, Ksaverska cesta 2, 10000, Zagreb, Croatia.
| |
Collapse
|
13
|
Chemical characterization, antioxidant, anti-inflammatory and cytotoxic properties of bee venom collected in Northeast Portugal. Food Chem Toxicol 2016; 94:172-7. [DOI: 10.1016/j.fct.2016.06.008] [Citation(s) in RCA: 68] [Impact Index Per Article: 8.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/27/2016] [Revised: 06/06/2016] [Accepted: 06/07/2016] [Indexed: 11/18/2022]
|
14
|
Gajski G, Domijan AM, Žegura B, Štern A, Gerić M, Novak Jovanović I, Vrhovac I, Madunić J, Breljak D, Filipič M, Garaj-Vrhovac V. Melittin induced cytogenetic damage, oxidative stress and changes in gene expression in human peripheral blood lymphocytes. Toxicon 2016; 110:56-67. [DOI: 10.1016/j.toxicon.2015.12.005] [Citation(s) in RCA: 39] [Impact Index Per Article: 4.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/04/2015] [Revised: 12/07/2015] [Accepted: 12/11/2015] [Indexed: 12/12/2022]
|